247 related articles for article (PubMed ID: 20385028)
1. Lack of evidence for KRAS oncogenic mutations in triple-negative breast cancer.
Sánchez-Muñoz A; Gallego E; de Luque V; Pérez-Rivas LG; Vicioso L; Ribelles N; Lozano J; Alba E
BMC Cancer; 2010 Apr; 10():136. PubMed ID: 20385028
[TBL] [Abstract][Full Text] [Related]
2. Molecular characterization of EGFR and EGFR-downstream pathways in triple negative breast carcinomas with basal like features.
Martin V; Botta F; Zanellato E; Molinari F; Crippa S; Mazzucchelli L; Frattini M
Histol Histopathol; 2012 Jun; 27(6):785-92. PubMed ID: 22473698
[TBL] [Abstract][Full Text] [Related]
3. Rare oncogenic mutations of predictive markers for targeted therapy in triple-negative breast cancer.
Grob TJ; Heilenkötter U; Geist S; Paluchowski P; Wilke C; Jaenicke F; Quaas A; Wilczak W; Choschzick M; Sauter G; Lebeau A
Breast Cancer Res Treat; 2012 Jul; 134(2):561-7. PubMed ID: 22610646
[TBL] [Abstract][Full Text] [Related]
4. [The role of KRAS gene mutation testing in colorectal cancer--a predictive biomarker of response to EGFR inhibitors therapy].
Rako I; Jakić-Razumović J; Caban D; Sertić J; Katalinić D; Golem H; Plestina S
Lijec Vjesn; 2011; 133(11-12):403-7. PubMed ID: 22329297
[TBL] [Abstract][Full Text] [Related]
5. High resolution melting analysis for rapid and sensitive EGFR and KRAS mutation detection in formalin fixed paraffin embedded biopsies.
Do H; Krypuy M; Mitchell PL; Fox SB; Dobrovic A
BMC Cancer; 2008 May; 8():142. PubMed ID: 18495026
[TBL] [Abstract][Full Text] [Related]
6. A 3'-untranslated region KRAS variant and triple-negative breast cancer: a case-control and genetic analysis.
Paranjape T; Heneghan H; Lindner R; Keane FK; Hoffman A; Hollestelle A; Dorairaj J; Geyda K; Pelletier C; Nallur S; Martens JW; Hooning MJ; Kerin M; Zelterman D; Zhu Y; Tuck D; Harris L; Miller N; Slack F; Weidhaas J
Lancet Oncol; 2011 Apr; 12(4):377-86. PubMed ID: 21435948
[TBL] [Abstract][Full Text] [Related]
7. Epidermal growth factor receptor and K-RAS status in two cohorts of squamous cell carcinomas.
Van Damme N; Deron P; Van Roy N; Demetter P; Bols A; Van Dorpe J; Baert F; Van Laethem JL; Speleman F; Pauwels P; Peeters M
BMC Cancer; 2010 May; 10():189. PubMed ID: 20459770
[TBL] [Abstract][Full Text] [Related]
8. Frequency and type of KRAS mutations in routine diagnostic analysis of metastatic colorectal cancer.
Neumann J; Zeindl-Eberhart E; Kirchner T; Jung A
Pathol Res Pract; 2009; 205(12):858-62. PubMed ID: 19679400
[TBL] [Abstract][Full Text] [Related]
9. Basal-like immunophenotype markers and prognosis in early breast cancer.
Cassol L; Silveira Graudenz M; Zelmanowicz A; Cancela A; Werutsky G; Rovere RK; Garicochea B
Tumori; 2010; 96(6):966-70. PubMed ID: 21388060
[TBL] [Abstract][Full Text] [Related]
10. [Detection of KRAS gene mutation and its clinical significance in colorectal adenocarcinoma].
Xu C; Liu YL; Huang J; He DM; Hou YY; Ji Y; Hou J; Lu SH; Xu JF; Hu Q; Shi Y; Zhao LJ; Tan YS
Zhonghua Bing Li Xue Za Zhi; 2012 Oct; 41(10):667-70. PubMed ID: 23302307
[TBL] [Abstract][Full Text] [Related]
11. Protein expression profile and prevalence pattern of the molecular classes of breast cancer--a Saudi population based study.
Al Tamimi DM; Shawarby MA; Ahmed A; Hassan AK; AlOdaini AA
BMC Cancer; 2010 May; 10():223. PubMed ID: 20492711
[TBL] [Abstract][Full Text] [Related]
12. Predominance of the basal type and HER-2/neu type in brain metastasis from breast cancer.
Gaedcke J; Traub F; Milde S; Wilkens L; Stan A; Ostertag H; Christgen M; von Wasielewski R; Kreipe HH
Mod Pathol; 2007 Aug; 20(8):864-70. PubMed ID: 17541441
[TBL] [Abstract][Full Text] [Related]
13. Basal cytokeratin and epidermal growth factor receptor expression are not predictive of BRCA1 mutation status in women with triple-negative breast cancers.
Collins LC; Martyniak A; Kandel MJ; Stadler ZK; Masciari S; Miron A; Richardson AL; Schnitt SJ; Garber JE
Am J Surg Pathol; 2009 Jul; 33(7):1093-7. PubMed ID: 19390427
[TBL] [Abstract][Full Text] [Related]
14. KRAS mutations in non-small-cell lung cancer and colorectal cancer: implications for EGFR-targeted therapies.
Maus MK; Grimminger PP; Mack PC; Astrow SH; Stephens C; Zeger G; Hsiang J; Brabender J; Friedrich M; Alakus H; Hölscher AH; Lara P; Danenberg KD; Lenz HJ; Gandara DR
Lung Cancer; 2014 Feb; 83(2):163-7. PubMed ID: 24331409
[TBL] [Abstract][Full Text] [Related]
15. KRAS mutations in Slovene patients with colorectal cancer: frequency, distribution and correlation with the response to treatment.
Licar A; Cerkovnik P; Ocvirk J; Novakovic S
Int J Oncol; 2010 May; 36(5):1137-44. PubMed ID: 20372787
[TBL] [Abstract][Full Text] [Related]
16. Triple-negative breast cancer with brain metastases: a comparison between basal-like and non-basal-like biological subtypes.
Niwińska A; Olszewski W; Murawska M; Pogoda K
J Neurooncol; 2011 Dec; 105(3):547-53. PubMed ID: 21656328
[TBL] [Abstract][Full Text] [Related]
17. KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial.
Richman SD; Seymour MT; Chambers P; Elliott F; Daly CL; Meade AM; Taylor G; Barrett JH; Quirke P
J Clin Oncol; 2009 Dec; 27(35):5931-7. PubMed ID: 19884549
[TBL] [Abstract][Full Text] [Related]
18. Comparison of targeted next-generation sequencing (NGS) and real-time PCR in the detection of EGFR, KRAS, and BRAF mutations on formalin-fixed, paraffin-embedded tumor material of non-small cell lung carcinoma-superiority of NGS.
Tuononen K; Mäki-Nevala S; Sarhadi VK; Wirtanen A; Rönty M; Salmenkivi K; Andrews JM; Telaranta-Keerie AI; Hannula S; Lagström S; Ellonen P; Knuuttila A; Knuutila S
Genes Chromosomes Cancer; 2013 May; 52(5):503-11. PubMed ID: 23362162
[TBL] [Abstract][Full Text] [Related]
19. Mutations in the epidermal growth factor receptor (EGFR) gene in triple negative breast cancer: possible implications for targeted therapy.
Teng YH; Tan WJ; Thike AA; Cheok PY; Tse GM; Wong NS; Yip GW; Bay BH; Tan PH
Breast Cancer Res; 2011 Apr; 13(2):R35. PubMed ID: 21457545
[TBL] [Abstract][Full Text] [Related]
20. Activating KRAS mutations and overexpression of epidermal growth factor receptor as independent predictors in metastatic colorectal cancer patients treated with cetuximab.
Yen LC; Uen YH; Wu DC; Lu CY; Yu FJ; Wu IC; Lin SR; Wang JY
Ann Surg; 2010 Feb; 251(2):254-60. PubMed ID: 20010090
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
